Atrial fibrillation patients do not benefit from acetylsalicylic acid

Europace

Volumn 16, Issue 5, 2014, Pages 631-638

  Själander, Sara ^a   Själander, Anders ^a   Svensson, Peter J ^b   Friberg, Leif ^c  

^a SUNDSVALL HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

Author keywords

Acetylsalicylic acid; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; ATRIAL FIBRILLATION; COHORT ANALYSIS; COMPLICATION; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; REGISTER; STROKE; SWEDEN; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; REGISTRIES; RETROSPECTIVE STUDIES; STROKE; SWEDEN; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84900330073     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut333     Document Type: Article

References (20)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
2. Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-81.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.
4. vanWalraven C, Hart RG, Connolly S, Austin PC, Mant J, HobbsFDet al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40: 1410-6.
5. Serdén L. Kodningskvalitet i patientregistret-slutenvard 2008 (available in Swedish only; Validity of the National Hospital Discharge Registry in Sweden). June 2010. Avaliable online at http://www.socialstyrelsen.se/ publikationer2010/2010-6-27.
6. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, ReuterwallCet al. External reviewand validation of the Swedish national inpatient register.BMCPublic Health 2011; 11: 450.
7. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-72.
8. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100.
9. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-80.
10. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
11. No authors listed. Stroke prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
12. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention on non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
13. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. J Neurol Sci 1997; 153: 112.
14. Posada IS, BarrialesV. Alternate-day dosing of aspirin in atrial fibrillation.LASAF Pilot Study Group. Am Heart J 1999; 138(Pt 1): 137-43.
15. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Antiplatelet therapy for preventing stroke in patients with atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000; (2): CD001925.
16. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial. Stroke 2006; 37: 447-51.
17. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-38.
18. Poli D, Antonucci E, Testa S, AgenoW, Palareti G; on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Res 2013; 131: 12-6.
19. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation, the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112: 1687-91.
20. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-413.